Kossoy L R, Herbert C M, Wentz A C
Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN 37232.
Am J Obstet Gynecol. 1988 Aug;159(2):490-9. doi: 10.1016/s0002-9378(88)80116-9.
As the number and survival time of heart transplant recipients continue to increase, their quality of life, including sexuality and childbearing, have become important issues. Reproduction is possible for both male and female patients after the transplant. Counseling for contraception when sterilization is not desired must take into account the increased risk of infection and genital carcinoma associated with immunosuppressant drug therapy. Teratogenicity has not been reported either with traditional immunosuppressive agents (prednisone, azathioprine) or with cyclosporine. Osteoporosis prophylaxis is particularly important in the female heart transplant recipient, because the chronic use of prednisone increases this risk. Guidelines are provided to counsel patients in these areas.
